{
    "clinical_study": {
        "@rank": "154594", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of\n      PF-06473871 in normal healthy adults."
        }, 
        "brief_title": "Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or females between the ages of 18 and 55 years inclusive\n\n        Exclusion Criteria:\n\n          -  Currently pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753791", 
            "org_study_id": "B5301002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1", 
                "description": "80 mg of PF-06473871 or placebo", 
                "intervention_name": "80 mg PF-06473871", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "description": "160 mg of PF-06473871 or placebo", 
                "intervention_name": "160 mg PF-06473871", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "description": "320 mg of PF-06473871 or placebo", 
                "intervention_name": "320 mg PF-06473871", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "description": "480 mg of PF-06473871 or placebo", 
                "intervention_name": "480 mg PF-06473871", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 19, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5301002&StudyName=Study%20To%20Evaluate%20Safety%2C%20Tolerability%2C%20And%20Pharmacokinetics%20Of%20PF-06473871%20In%20Normal%20healthy%20Adults%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Dose Expansion Of A Within-Cohort, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-And Multiple-Dose Escalation Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "pulse rate", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Injection siter reaction", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753791"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Area under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}